Browsing Tag
Samsung Biologics
4 posts
GSK offloads Human Genome Sciences: what’s next for Samsung Biologics’ global ambitions?
Samsung Biologics acquires Human Genome Sciences from GSK for $280M, gaining its first U.S. biologics plant. Find out what this move means for global CDMO strategy.
LOTTE BIOLOGICS secures third major contract of 2025 through new U.S. biopharma manufacturing deal
LOTTE BIOLOGICS wins a third U.S. contract in 2025, boosting its CDMO momentum and investor sentiment. Find out how the deal shapes biomanufacturing strategy.
FDA acceptance of Sarfaraz Niazi’s biosimilar petition could reset the economics of monoclonal antibody approvals
FDA accepts Sarfaraz Niazi’s petition to waive costly clinical efficacy studies for monoclonal antibody biosimilars, reshaping drug affordability worldwide.
Samsung Biologics bags $1.24bn CDMO contract with Asia-based pharma firm
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), has signed its largest-ever contract, valued…